We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+3.41%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$118M
AUM Growth
-$12M
Cap. Flow
-$24.6M
Cap. Flow %
-20.81%
Top 10 Hldgs %
43.16%
Holding
94
New
22
Increased
10
Reduced
13
Closed
18

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$7.61M
2
XNPT
XENOPORT, INC.
XNPT
+$2.71M
3
ACHN
Achillion Pharmaceuticals
ACHN
+$2.26M
4
OTIC
Otonomy, Inc.
OTIC
+$1.72M
5
CYAD
Celyad Oncology SA American Depositary Shares
CYAD
+$1.61M

Top Sells

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$18.3M
2
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$12.1M
3
MTEM
Molecular Templates, Inc.
MTEM
+$2.54M
4
ATRC icon
AtriCure
ATRC
+$1.98M
5
CRIS icon
Curis
CRIS
+$720K

Sector Composition

Rank Sector Weight
1 Healthcare 72.51%
2 Financials 0.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MBAI
51
Check-Cap
MBAI
$8.04M
$385K 0.33%
458
– –
APTO
52
DELISTED
Aptose Biosciences, Inc.
APTO
$359K 0.3%
156
+106
+212% +$277K
PVLA
53
Palvella Therapeutics
PVLA
$2.05B
$344K 0.29%
+1,563
New +$344K
RIOT icon
54
Riot Platforms
RIOT
$6.9B
$295K 0.25%
82,250
– –
MRNS
55
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$259K 0.22%
+5,580
New +$208K
ATNM icon
56
Actinium Pharmaceuticals
ATNM
$26.3M
$239K 0.2%
3,000
– –
ALPN
57
DELISTED
Alpine Immune Sciences Inc
ALPN
$227K 0.19%
+3,750
New +$223K
LOXO
58
DELISTED
Loxo Oncology, Inc
LOXO
$221K 0.19%
+12,245
New +$167K
CVM icon
59
CEL-SCI Corp
CVM
$19.9M
$209K 0.18%
+422
New +$268K
GNVC
60
DELISTED
GenVec, Inc.
GNVC
$204K 0.17%
10,000
– –
BITI
61
DELISTED
BIOTIE THERAPIES CORP SPONSORED ADR
BITI
$200K 0.17%
+10,000
New +$209K
LSTA icon
62
Lisata Therapeutics
LSTA
$9.93M
$166K 0.14%
+593
New +$220K
CASC
63
DELISTED
Cascadian Therapeutics, Inc.
CASC
$135K 0.11%
+6,030
New +$95.4K
CEMI
64
DELISTED
Chembio diagnostics, Inc.
CEMI
$129K 0.11%
26,287
– –
TTHI
65
DELISTED
TRANSITION THERAPEUTICS INC (CANADA)
TTHI
$124K 0.1%
59,222
+32,812
+124% +$230K
CRBP icon
66
Corbus Pharmaceuticals
CRBP
$165M
$113K 0.1%
+1,220
New +$123K
CASM
67
DELISTED
CAS Medical Systems, Inc.
CASM
$113K 0.1%
88,522
-11,478
-11% -$14.9K
CHEKW
68
DELISTED
Check-Cap Ltd. Series A Warrant
CHEKW
$96K 0.08%
55,000
– –
ATRS
69
DELISTED
Antares Pharma, Inc.
ATRS
$94K 0.08%
+45,000
New +$109K
ALDX icon
70
Aldeyra Therapeutics
ALDX
$97.1M
– –
-35,000
Closed -$356K
APYX icon
71
Apyx Medical
APYX
$162M
– –
-100,000
Closed -$239K
CRIS icon
72
Curis
CRIS
$9.71M
– –
-150
Closed -$720K
FATE icon
73
Fate Therapeutics
FATE
$275M
– –
-20,190
Closed -$99K
NERV icon
74
Minerva Neurosciences
NERV
$191M
– –
-12,665
Closed -$507K
TNXP icon
75
Tonix Pharmaceuticals
TNXP
$152M
– –
0
– -$91K
1 2
3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
CPW
Cove Private Wealth Oyster Bay Cove, New York $440M AUM 27.56% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
DWML
Decker Wealth Management LLC Nashville, Tennessee $441M AUM

DAFNA Capital Management's Q2 2015 Portfolio in Review

As of Q2 2015, DAFNA Capital Management held 94 positions worth $118M, down 9.2% from $130M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

DAFNA Capital Management withdrew a net $24.6M in Q2 2015, closing 18 positions and reducing 13 holdings. Its most notable exit was PHARMACYCLICS INC, an estimated $18.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, up from 56% a quarter earlier, followed by Financials.

Against the trend, DAFNA Capital Management opened a new position in AbbVie worth $7.83M.

  • DAFNA Capital Management's largest Q2 2015 buy was AbbVie: 116,581 shares worth $7.83M.
  • DAFNA Capital Management added most to XENOPORT, INC. in Q2 2015, an estimated $2.71M increase.
  • DAFNA Capital Management's biggest Q2 2015 reduction was AtriCure, cutting an estimated $1.98M.
  • DAFNA Capital Management fully exited PHARMACYCLICS INC in Q2 2015, selling an estimated $18.3M.
  • DAFNA Capital Management's ten largest holdings make up 43% of its $118M portfolio in Q2 2015.
  • DAFNA Capital Management opened 22 new positions and closed 18 in Q2 2015.
  • DAFNA Capital Management's portfolio value fell 9.2% quarter-over-quarter to $118M.

Based on DAFNA Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.